**C3RN News Summary – June 18rd, 2019**

Research

Researchers examining trends in opioid overdoses relating to legalization of cannabis challenges previous research and states that “cannabinoids have demonstrated therapeutic benefits… but reducing population-level opioid overdose mortality does not appear to be among them.”

[June 10, 2019: Stanford University, CA](https://www.pnas.org/content/early/2019/06/04/1903434116)

Researchers conducting “a secondary data analysis study to determine whether previously observed acute effects of tetrahydrocannabinol (THC) on mood was dependent upon variation in *CNR1…”* posit “these preliminary findings suggest individual differences in mood states after using marijuana depend on genetic variation. Such information might be useful in understanding either motivation for use of marijuana and/or risk for associated behaviors.”

[June 11, 2019: Emory University, GA](file:///C:\Users\DJR52\OneDrive\c3rn\Newsletter\June%20Newsletters\June%2011,%202019:)

A study designed “to determine if a cannabinoid agonist could potentiate opioid analgesia in humans” concludes that their findings “suggest that dronabinol [cannabinoid agonist] may not be an effective or appropriate opioid adjuvant; it could potentially increase opioid dose requirements, while increasing psychoactive opioid effects.”

[June 15, 2019: University of Kentucky, KY](https://link.springer.com/article/10.1007%2Fs00213-019-05293-1)

A study “tested the utility of an online personalized feedback intervention (PFI) that integrates feedback regarding cannabis with strategies to manage negative affect” and the authors conclude that “results of this pilot study indicate a 1-session intervention that teaches simultaneously teaching skills to manage negative affect and cannabis may benefit some cannabis users with moderate to high social anxiety.”

[June 17, 2019: University of Houston, TX](https://psycnet.apa.org/doiLanding?doi=10.1037%2Fpha0000304)

Industry News

Kenneth L. Davis, the president and chief executive of the Mount Sinai Health System, and Mary Jeanne Kreek, the head of Laboratory of the Biology of Addictive Diseases at Rockefeller University wrote an op-ed that posits that “states that legalize marijuana should set a minimum age of no younger than 25. They should also impose stricter limits on THC levels and strictly monitor them. Educational campaigns are also necessary to help the public understand that marijuana is not harmless.”

[June 16, 2019: NY Times](https://www.nytimes.com/2019/06/16/opinion/marijuana-brain-effects.html?action=click&module=Opinion&pgtype=Homepage)